Skip to main content
Equibles

GSA CAPITAL PARTNERS LLP

Position in EDIT — Editas Medicine, Inc.

CIK 1362033 LONDON, X0
Back to EDIT Full portfolio

Position in EDIT

as of Jun 30, 2026 · filed Aug 6, 2026
Position Value
$1,189,556
+$116,556 QoQ
Shares Held
367,147
-15.5% QoQ
Ownership
0.239%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#39
of 216 holders
Holding Since
Sep 2021
15 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in EDIT Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names. EDIT ranks #26 (1.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 IOVA
Iovance Biotherapeutics, Inc.
 655,318 $2,726,122
2 IMVT
Immunovant, Inc.
 65,267 $2,514,737
3 GOSS
Gossamer Bio, Inc.
 14,986,947 $2,472,846
4 AXSM
Axsome Therapeutics, Inc.
 9,419 $2,305,488
5 CABA
Cabaletta Bio, Inc.
 668,563 $2,079,230
6 MLTX
MoonLake Immunotherapeutics
 106,695 $2,077,351
7 ATYR
aTYR PHARMA INC
 3,454,863 $2,062,553
8 CORT
Corcept Therapeutics Inc
 23,257 $2,022,196

All Filings in EDIT

Export CSV
15 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,189,556 367,147
2026-03-31 $1,073,000 434,413
2025-12-31 $1,166,058 568,809
2025-06-30 $181,154 82,343
2024-09-30 $623,092 182,725
2024-06-30 $451,612 96,705
2024-03-31 $351,722 47,402
2023-09-30 $157,099 20,141
2023-03-31 $148,980 20,549
2022-12-31 $166,277 18,746
2022-09-30 $250,993 20,506
2022-06-30 $816,270 69,000
2022-03-31 $230,598 12,124
2021-12-31 $297,386 11,201
2021-09-30 $281,973 6,864